The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients
The 2019 coronavirus disease (COVID-19)-associated coagulopathy one of the significant complications often found in hospitalized COVID-19 patients. A hypercoagulable and prothrombotic state characterize coagulopathy with an increased risk of thrombotic events. Abnormal coagulation tests could predic...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Airlangga
2022-05-01
|
| Series: | Jurnal Respirasi |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/JR/article/view/31015 |
| _version_ | 1818238199529472000 |
|---|---|
| author | Yosua Butar Butar Yetti Hernaningsih Narazah Mohd Yusoff |
| author_facet | Yosua Butar Butar Yetti Hernaningsih Narazah Mohd Yusoff |
| author_sort | Yosua Butar Butar |
| collection | DOAJ |
| description | The 2019 coronavirus disease (COVID-19)-associated coagulopathy one of the significant complications often found in hospitalized COVID-19 patients. A hypercoagulable and prothrombotic state characterize coagulopathy with an increased risk of thrombotic events. Abnormal coagulation tests could predict bleeding risk, thrombosis, and disease severity. In addition to increasing the D-dimer, prolonged prothrombin time has decreased survival and increased treatment requirements. Based on laboratory findings, it was reported that 70% of patients with COVID-19 had disseminated intravascular coagulation (DIC) and 30% had thrombosis. Approximately 8% of patients with COVID-19 have hemorrhagic complications, the most common one is gastrointestinal bleeding. Variations in hypercoagulability and bleeding occur in COVID-19 patients. Therefore, the anticoagulant drug should be considered to minimize bleeding risk. An anti-bleeding agent for bleeding complications should be considered for the potential increase of coagulopathy. Thromboelastography (TEG) is a tool that is used to analyze the characteristics of viscoelastic clots, platelet function, and fibrinolysis in whole blood, providing a complete picture of the patient's coagulation status. From various therapeutic guidelines for COVID-19 patients, heparin is used as an anticoagulant drug to prevent thrombosis in COVID-19 patients. Starting from prophylactic doses to therapeutic doses, heparin is used to prevent the severity of COVID-19 patient course. The effect of coagulation on COVID-19 patients varies from no impact to hypercoagulation in TEG results. |
| first_indexed | 2024-12-12T12:37:51Z |
| format | Article |
| id | doaj.art-99f2172698474dc58a78ffd942a83d66 |
| institution | Directory Open Access Journal |
| issn | 2407-0831 2621-8372 |
| language | English |
| last_indexed | 2024-12-12T12:37:51Z |
| publishDate | 2022-05-01 |
| publisher | Universitas Airlangga |
| record_format | Article |
| series | Jurnal Respirasi |
| spelling | doaj.art-99f2172698474dc58a78ffd942a83d662022-12-22T00:24:18ZengUniversitas AirlanggaJurnal Respirasi2407-08312621-83722022-05-0182119125https://doi.org/10.20473/jr.v8-I.2.2022.119-125The Role of Thromboelastography in Heparin Therapy for COVID-19 PatientsYosua Butar Butar0https://orcid.org/0000-0001-7385-817XYetti Hernaningsih1https://orcid.org/0000-0001-8773-8267Narazah Mohd Yusoff2https://orcid.org/0000-0001-6801-2508Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.Regenerative Medicine Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia.The 2019 coronavirus disease (COVID-19)-associated coagulopathy one of the significant complications often found in hospitalized COVID-19 patients. A hypercoagulable and prothrombotic state characterize coagulopathy with an increased risk of thrombotic events. Abnormal coagulation tests could predict bleeding risk, thrombosis, and disease severity. In addition to increasing the D-dimer, prolonged prothrombin time has decreased survival and increased treatment requirements. Based on laboratory findings, it was reported that 70% of patients with COVID-19 had disseminated intravascular coagulation (DIC) and 30% had thrombosis. Approximately 8% of patients with COVID-19 have hemorrhagic complications, the most common one is gastrointestinal bleeding. Variations in hypercoagulability and bleeding occur in COVID-19 patients. Therefore, the anticoagulant drug should be considered to minimize bleeding risk. An anti-bleeding agent for bleeding complications should be considered for the potential increase of coagulopathy. Thromboelastography (TEG) is a tool that is used to analyze the characteristics of viscoelastic clots, platelet function, and fibrinolysis in whole blood, providing a complete picture of the patient's coagulation status. From various therapeutic guidelines for COVID-19 patients, heparin is used as an anticoagulant drug to prevent thrombosis in COVID-19 patients. Starting from prophylactic doses to therapeutic doses, heparin is used to prevent the severity of COVID-19 patient course. The effect of coagulation on COVID-19 patients varies from no impact to hypercoagulation in TEG results.https://e-journal.unair.ac.id/JR/article/view/31015covid-19heparininfectious diseasethromboelastography |
| spellingShingle | Yosua Butar Butar Yetti Hernaningsih Narazah Mohd Yusoff The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients Jurnal Respirasi covid-19 heparin infectious disease thromboelastography |
| title | The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients |
| title_full | The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients |
| title_fullStr | The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients |
| title_full_unstemmed | The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients |
| title_short | The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients |
| title_sort | role of thromboelastography in heparin therapy for covid 19 patients |
| topic | covid-19 heparin infectious disease thromboelastography |
| url | https://e-journal.unair.ac.id/JR/article/view/31015 |
| work_keys_str_mv | AT yosuabutarbutar theroleofthromboelastographyinheparintherapyforcovid19patients AT yettihernaningsih theroleofthromboelastographyinheparintherapyforcovid19patients AT narazahmohdyusoff theroleofthromboelastographyinheparintherapyforcovid19patients AT yosuabutarbutar roleofthromboelastographyinheparintherapyforcovid19patients AT yettihernaningsih roleofthromboelastographyinheparintherapyforcovid19patients AT narazahmohdyusoff roleofthromboelastographyinheparintherapyforcovid19patients |